自身免疫性肝炎和原发性胆汁性肝硬化患者自身免疫性甲状腺疾病流行率调查*

doi:10.3969/j.issn.1672-5069.2022.01.011

摘要/Abstract

摘要： 目的调查自身免疫性肝病(AILD)患者自身免疫性甲状腺疾病(AITD)发病率情况。方法 2018年6月～2020年12月我院诊治的自身免疫性肝炎(AIH)41例和原发性胆汁性肝硬化(PBC)患者45例,采用间接免疫荧光法或免疫印迹法检测血清抗核抗体(ANA)、抗线粒体抗体(AMA)或AMA-M2)、抗平滑肌抗体(ASMA)、抗双链DNA抗体(抗dsDNA)和抗着丝点抗体(ACA);采用ELISA法检测血清免疫球蛋白,包括IgG、IgM和γ-球蛋白。结果在本组41例AIH患者中,合并HT患者12例,合并GD患者6例,在45例PBC患者中,合并HT患者8例,合并GD患者7例;AIH患者血清IgG水平为17.5(14.8,19.8)g/L,显著低于AIH合并HT组【21.6(17.5,29.0)g/L,P<0.05】或AIH合并GD组【22.4(20.2,26.4)g/L,P<0.05】,血清γ-球蛋白为22.2(19.3,25.6)%,显著低于合并HT组【26.5(22.2,32.2)%,P<0.05】或合并GD组【27.1(24.3,32.0)%,P<0.05】;PBC患者年龄为(55.2±1.1)岁,显著小于合并HT组【(62.4±1.6)岁,P<0.05】或合并GD组【(62.2±1.5)岁,P<0.05】,血清IgG水平为15.4(12.2,18.0)g/L,显著低于合并HT组【20.3(16.8,24.7)g/L,P<0.05】或合并GD组【21.3(16.8,25.6)g/L,P<0.05】,血清γ-球蛋白水平为21.2(17.8,25.6)%,显著低于合并HT组【26.7(21.7,30.4)%,P<0.05】或合并GD组【25.4(22.2,29.4)%,P<0.05】。结论 AILD合并AITD的发病率较高,合并AITD患者血清IgG和γ-球蛋白水平较高,其原因还有待于进一步研究。

关键词: 自身免疫性肝炎, 原发性胆汁性肝硬化, 自身免疫性甲状腺疾病, 流行

Abstract: Objective The aim of this study was to investigate the coincidence of autoimmune thyroid diseases (AITD) in patients with autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC). Methods A total of 41 patients with AIH and 45 patients with PBC were recruited in this study between June 2018 and December 2020, and serum anti-nuclear antibody (ANA), anti-mitochondrial antibody (AMA) and/or anti-mitochondrial antibody M2 (AMA-M2), anti-smooth muscle antibody (ASMA), anti-double-stranded DNA antibody (anti-dsDNA) and anti-centromere antibody (ACA) were detected. Results Out of 41 patients with AIH in our series, 12 patients had Hashimoto's thyroiditis (HT), and 6 had Grave's disease (GD), and out of 45 patients with PBC, 8 had HT, and 7 had GD; serum IgG level in patients with AIH was 17.5(14.8,19.8)g/L, significantly lower than [21.6(17.5, 29.0)g/L, P<0.05] in patients with AIH and HT or [22.4(20.2, 26.4)g/L, P<0.05] in patients with AIH and GD, serum γ-globulin level was 22.2(19.3, 25.6)%, significantly lower than [26.5(22.2, 32.2)%, P<0.05] in patients with AIH and HT or [27.1(24.3, 32.0)%, P<0.05] in patients with AIH and GD; the age of patients with PBC was (55.2±1.1)yr old, significantly younger than [(62.4±1.6) yr old, P<0.05] in patients with PBC and HT or [(62.2±1.5)yr old, P<0.05] in patients with PBC and GD, serum IgG level was 15.4(12.2, 18.0)g/L, significantly lower than [20.3(16.8, 24.7)g/L, P<0.05] in patients with PBC and HT or [21.3(16.8, 25.6)g/L, P<0.05] in patients with PBC and GD, serum γ-globulin level was 21.2(17.8, 25.6)%, significantly lower than [26.7(21.7, 30.4)%, P<0.05] in PBC patients with HT or [25.4(22.2, 29.4)%, P<0.05] in patients with PBC and GD. Conclusion The coincidence of AITD in patients with AILD is common, and serum IgG and γ-globulin levels increase in patients with AIH or PBC with concomitant AITD, which needs further investigation.

Key words: Autoimmune hepatitis, Primary biliary cirrhosis, Autoimmune thyroid diseases, Prevalence

徐艳, 于秉楠, 武剑. 自身免疫性肝炎和原发性胆汁性肝硬化患者自身免疫性甲状腺疾病流行率调查^*[J]. 实用肝脏病杂志, 2022, 25(1): 42-45.

Xu Yan, Yu Bingnan, Wu Jian. Coincidence of autoimmune thyroid diseases in patients with autoimmune hepatitis and primary biliary cirrhosis[J]. Journal of Practical Hepatology, 2022, 25(1): 42-45.

参考文献

[1] Duclos-Vallee JC, Sebagh M. Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation. Liver Transpl, 2009, 15 (Suppl 2): S25-S34.
[2] Harnois DM, Yataco ML, Nakhleh RE. Recurrence of autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis after transplantation. Clin Liver Dis (Hoboken), 2014, 3(4): 90-92.
[3] Lee HJ, Li CW, Hammerstad SS, et al. Immunogenetics of autoimmune thyroid diseases: a comprehensive review. J Autoimmun, 2015, 64: 82-90.
[4] Inoue N, Katsumata Y, Watanabe M, et al. Polymorphisms and expression of toll-like receptors in autoimmune thyroid diseases. Autoimmunity, 2017, 50: 182-191.
[5] Chalifoux SL, Konyn PG, Choi G, et al. Extrahepatic manifestations of primary biliary cholangitis. Gut Liver, 2017, 11: 771-780.
[6] Wong GW, Heneghan MA. Association of extrahepatic manifestations with autoimmune hepatitis. Dig Dis, 2015, 33: 25-35.
[7] Teufel A, Weinmann A, Kahaly GJ, et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol, 2010, 44: 208-213.
[8] Muratori P, Fabbri A, Lalanne C, et al. Autoimmune liver disease and concomitant extrahepatic autoimmune disease. Eur J Gastroenterol Hepatol, 2015, 27: 1175-1179.
[9] Wong GW, Yeong T, Lawrence D, et al. Concurrent extrahepatic autoimmunity in autoimmune hepatitis: implications for diagnosis, clinical course and long-term outcomes. Liver Int, 2017, 37: 449-457.
[10] Floreani A, Mangini C, Reig A, et al. Thyroid dysfunction in primary biliary cholangitis: a comparative study at two European centers. Am J Gastroenterol, 2017, 112: 114-119.
[11] Nakamura H, Usa T, Motomura M, et al. Prevalence of interrelated autoantibodies in thyroid diseases and autoimmune disorders. J Endocrinol Invest, 2008, 31: 861-865.
[12] Fiducia M, Lauretta R, Lunghi R, et al. Hashimoto's thyroiditis and autoimmunity parameters: descriptive study. Minerva Med, 2007, 98: 95-99.
[13] Sebode M, Hartl J, Vergani D, et al. Autoimmune hepatitis: from current knowledge and clinical practice to future research agenda. Liver Int, 2018, 38(1): 15-22.
[14] Alfano AM, RomitoA, Marchese C, et al. Diagnostic accuracy of two tests for determination of anti-m2 in the diagnosis of primary biliary cirrhosis: is it possible to predict the course of the disease? Immunol Res, 2017, 65(1): 299-306.
[15] Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol, 1995, 19: 1409-1417.
[16] Floreani A, De Martin S, Secchi MF, et al. Extrahepatic autoimmunity in autoimmune liver disease. Eur J Intern Med, 2019, 59: 1-7.
[17] Crowe JP, Christensen E, Butler J, et al. Primary biliary cirrhosis: the prevalence of hypothyroidism and its relationship to thyroid autoantibodies and sicca syndrome. Gastroenterology, 1980, 78: 1437-1441.
[18] Kawashima ST, Tagami T, Nakao K, et al. Serum levels of IgG and IgG4 in Hashimoto thyroiditis. Endocrine, 2014, 45: 236-243.
[19] Yamauchi K, Yamada T, Sato A, et al. Elevation of serum immunoglobulin G in Hashimoto's thyroiditis and decrease after treatment with L-thyroxine in hypothyroid patients. Intern Med, 2010, 49: 267-271.
[20] Zeng Q, Zhao L, WangC, et al. Relationship between autoimmune liver disease and autoimmune thyroid disease: a cross-sectional study. Scand J Gastroenterol, 2020, 55(2): 216-221.
[21] Kus A, Arlukowicz-Grabowska M, Szymanski K, et al. Genetic risk factors for autoimmune thyroid disease might affect the susceptibility to and modulate the progression of primary biliary cholangitis. J Gastrointestin Liver Dis, 2017, 26: 245-252.
[22] Tojo J, Ohira H, Suzuki T, et al. Clinicolaboratory characteristics of patients with primary biliary cirrhosis associated with CREST symptoms. Hepatol Res, 2002, 22: 187-195.
[23] Tsianos EV, Hoofnagle JH, Fox PC, et al. Sjogren's syndrome in patients with primary biliary cirrhosis. Hepatology, 1990, 11: 730-734.
[24] Floreani A, Franceschet I, Cazzagon N, et al. Extrahepatic autoimmune conditions associated with primary biliary cirrhosis. Clinic Rev Allerg Immunol, 2015, 48: 192-197.

自身免疫性肝炎和原发性胆汁性肝硬化患者自身免疫性甲状腺疾病流行率调查^*

Coincidence of autoimmune thyroid diseases in patients with autoimmune hepatitis and primary biliary cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨蕊旭, 范建高. 非酒精性脂肪性肝病相关肝细胞癌流行病学与筛查^*[J]. 实用肝脏病杂志, 2022, 25(2): 153-156.
[2]	马国斌, 赵晓宏, 赵鹏, 杨冰. 自身免疫性肝炎患者肝组织IL-35表达和外周血髓样抑制细胞百分比变化临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(2): 199-202.
[3]	郑小勤, 徐辉, 李丽, 靳华, 汪晓军, 勾春燕. 家族聚集性原发性胆汁性肝硬化患者临床特征分析[J]. 实用肝脏病杂志, 2022, 25(2): 207-210.
[4]	梁烨倍, 杨春光, 王昆凤, 胡秋明, 李妍辉, 罗琴, 陈浩, 郑亚雄, 余俊, 唐小英, 史华祥, 牛涛, 吴伟, 侯旭宏, 贾伟平. 云南省布朗族成人非酒精性脂肪性肝病流行特点研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 223-226.
[5]	史雪丽, 张万里, 毛俊, 颜悦蓉. 自身免疫性肝炎大鼠血清IL-38和β2GPI水平及其与肝组织病变的关系^*[J]. 实用肝脏病杂志, 2021, 24(6): 803-806.
[6]	肖金玉, 王延峰, 文小霞. 自身免疫性肝炎患者血清趋化因子CCL4和CXCL10水平及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(6): 827-830.
[7]	吴晓枫, 黄怡, 杨如杏, 邓少东, 张静莹, 官成浓, 王颖. 原发性胆汁性肝硬化患者外周血丝氨酸蛋白酶抑制剂A1基因多态性分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 855-858.
[8]	何勇, 张振华, 刘忠萍, 伍宵, 孙秋林. 中国HCV基因型分布的Meta分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 693-696.
[9]	王绮夏, 马雄. 自身免疫性肝病精准诊治与临床转化研究的思考^*[J]. 实用肝脏病杂志, 2021, 24(4): 457-459.
[10]	李变利, 徐丽红. 药物性肝损伤、药物诱导性自身免疫性肝炎和自身免疫性肝炎鉴别诊断研究进展^*[J]. 实用肝脏病杂志, 2021, 24(4): 460-463.
[11]	梁玉萍, 粟全球, 张慧, 王佳林. 自身免疫性肝炎患者维生素D缺乏调查及其临床特征分析^*[J]. 实用肝脏病杂志, 2021, 24(4): 464-467.
[12]	刘娜, 张华敏, 邓巧娟. 抑制TRAF6基因表达对自身免疫性肝炎大鼠肝组织NF-κB信号通路相关蛋白表达的影响[J]. 实用肝脏病杂志, 2021, 24(4): 468-471.
[13]	李拓键, 张超, 陈宗涛. 重庆市800名教职工健康体检脂肪肝检出情况分析^*[J]. 实用肝脏病杂志, 2021, 24(4): 512-515.
[14]	齐玫, 张瑞金, 田树萍, 于艳华. 平均血小板体积对自身免疫性肝炎患者治疗不应答的预测价值分析[J]. 实用肝脏病杂志, 2021, 24(3): 371-374.
[15]	白洁, 任艳, 梁晨, 汤珊, 刘念晨, 白丽, 刘霜, 郑素军, 段钟平. 1996～2020年北京佑安医院遗传代谢性肝病住院患者流行病学特征分析[J]. 实用肝脏病杂志, 2021, 24(2): 164-167.